文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

针对肝巨噬细胞治疗肝脏疾病。

Targeting hepatic macrophages to treat liver diseases.

机构信息

Department of Medicine III, University Hospital Aachen, Aachen, Germany.

出版信息

J Hepatol. 2017 Jun;66(6):1300-1312. doi: 10.1016/j.jhep.2017.02.026. Epub 2017 Mar 4.


DOI:10.1016/j.jhep.2017.02.026
PMID:28267621
Abstract

UNLABELLED: Our view on liver macrophages in the context of health and disease has been reformed by the recognition of a remarkable heterogeneity of phagocytes in the liver. Liver macrophages consist of ontogenically distinct populations termed Kupffer cells and monocyte-derived macrophages. Kupffer cells are self-renewing, resident and principally non-migratory phagocytes, serving as sentinels for liver homeostasis. Liver injury triggers Kupffer cell activation, leading to inflammatory cytokine and chemokine release. This fosters the infiltration of monocytes into the liver, which give rise to large numbers of inflammatory monocyte-derived macrophages. Liver macrophages are very plastic and adapt their phenotype according to signals derived from the hepatic microenvironment (e.g. danger signals, fatty acids, phagocytosis of cellular debris), which explains their manifold and even opposing functions during disease. These central functions include the perpetuation of inflammation and hepatocyte injury, activation of hepatic stellate cells with subsequent fibrogenesis, and support of tumor development by angiogenesis and T cell suppression. If liver injury ceases, specific molecular signals trigger hepatic macrophages to switch their phenotype towards reparative phagocytes that promote tissue repair and regression of fibrosis. Novel strategies to treat liver disease aim at targeting macrophages. These interventions modulate Kupffer cell activation (e.g. via gut-liver axis or inflammasome formation), monocyte recruitment (e.g. via inhibiting chemokine pathways like CCR2 or CCL2) or macrophage polarization and differentiation (e.g. by nanoparticles). Evidence from mouse models and early clinical studies in patients with non-alcoholic steatohepatitis and fibrosis support the notion that pathogenic macrophage subsets can be successfully translated into novel treatment options for patients with liver disease. LAY SUMMARY: Macrophages (Greek for "big eaters") are a frequent non-parenchymal cell type of the liver that ensures homeostasis, antimicrobial defense and proper metabolism. However, liver macrophages consist of different subtypes regarding their ontogeny (developmental origin), differentiation and function. Understanding this heterogeneity and the critical regulation of inflammation, fibrosis and cancer by macrophage subsets opens promising new options for treating liver diseases.

摘要

未加标签:我们对健康和疾病中肝巨噬细胞的看法已经被认识到肝内吞噬细胞具有显著异质性所改变。肝巨噬细胞由称为库普弗细胞和单核细胞衍生的巨噬细胞的两个不同的发育群体组成。库普弗细胞是自我更新的、常驻的、主要是非迁移性的吞噬细胞,充当着肝脏内稳态的哨兵。肝损伤触发库普弗细胞激活,导致炎症细胞因子和趋化因子的释放。这促进了单核细胞浸润肝脏,从而产生大量的炎症性单核细胞衍生的巨噬细胞。肝巨噬细胞非常有可塑性,并根据来自肝微环境的信号(例如危险信号、脂肪酸、细胞碎片的吞噬作用)来调节其表型,这解释了它们在疾病过程中具有多种甚至相反的功能。这些核心功能包括炎症和肝细胞损伤的持续存在、肝星状细胞的激活以及随后的纤维化形成、血管生成和 T 细胞抑制支持肿瘤发展。如果肝损伤停止,特定的分子信号会触发肝巨噬细胞向促进组织修复和纤维化消退的修复性吞噬细胞转变。针对肝脏疾病的新型治疗策略旨在靶向巨噬细胞。这些干预措施调节库普弗细胞的激活(例如通过肠道-肝脏轴或炎性小体形成)、单核细胞的募集(例如通过抑制趋化因子途径如 CCR2 或 CCL2)或巨噬细胞的极化和分化(例如通过纳米颗粒)。来自小鼠模型和非酒精性脂肪性肝炎和纤维化患者的早期临床研究的证据支持这样一种观点,即致病性巨噬细胞亚群可以成功地转化为肝脏疾病患者的新型治疗选择。

概述:巨噬细胞(希腊语为“大食者”)是肝脏中常见的非实质细胞类型,可确保内稳态、抗菌防御和适当的代谢。然而,肝巨噬细胞在其发生、分化和功能上存在不同的亚型。了解这种异质性以及巨噬细胞亚群对炎症、纤维化和癌症的关键调控为治疗肝脏疾病提供了有希望的新选择。

相似文献

[1]
Targeting hepatic macrophages to treat liver diseases.

J Hepatol. 2017-3-4

[2]
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.

Hepatology. 2018-2-19

[3]
Macrophage heterogeneity in liver injury and fibrosis.

J Hepatol. 2014-1-8

[4]
Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases.

Front Immunol. 2019-12-3

[5]
Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice.

Hepatology. 2014-1-30

[6]
Macrophage Phenotype and Function in Liver Disorder.

Front Immunol. 2020-1-28

[7]
Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2.

Am J Physiol Gastrointest Liver Physiol. 2012-3-22

[8]
Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production.

J Biol Chem. 2012-10-12

[9]
Monocytes and macrophages as cellular targets in liver fibrosis.

Inflamm Allergy Drug Targets. 2009-9

[10]
Dynamic plasticity of macrophage functions in diseased liver.

Cell Immunol. 2017-12-20

引用本文的文献

[1]
Cytoprotective effect of prostacyclin on hepatic ischemia-reperfusion injury.

World J Methodol. 2025-12-20

[2]
Fucoidan from alleviates MetALD via promoting HIF-1α ubiquitination to suppress peripheral monocyte infiltration.

Front Pharmacol. 2025-8-15

[3]
CXCR6 recruits Th2 cells and promotes liver fibrosis in schistosomiasis japonica.

Hepatol Commun. 2025-8-26

[4]
8-Methoxybicolosin C from Attenuates Inflammation and Oxidative Stress via Nrf2/HO-1 and NF-κB/MAPK Pathways in Lipopolysaccharide-Induced Mouse Kupffer Cells.

J Microbiol Biotechnol. 2025-8-18

[5]
: A Review of Its Effects on Immune Organs.

Microorganisms. 2025-7-9

[6]
The Beneficial Effects of Resveratrol on Hepatocellular Carcinoma and Nonalcoholic Fatty Liver Disease: Modulation of Apoptosis, Autophagy, Inflammation, and Oxidative Stress.

Food Sci Nutr. 2025-7-24

[7]
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease.

JHEP Rep. 2025-4-11

[8]
Inflammation in MASLD progression and cancer.

JHEP Rep. 2025-4-2

[9]
MASLD development: From molecular pathogenesis toward therapeutic strategies.

Chin Med J (Engl). 2025-8-5

[10]
Perisurgical colony stimulating factor one treatment ameliorates liver ischaemia/reperfusion injury in rats.

World J Gastroenterol. 2025-6-28

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索